BACKGROUND: Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations. However, in Japan, HCQ has not been approved for CLE or SLE. To establish an appropriate therapeutic regimen and to clarify the pharmacokinetics (PK) of HCQ in Japanese patients with CLE with or without SLE (CLE/SLE), a population pharmacokinetic (PopPK) analysis was performed. METHODS: In a clinical study of Japanese patients with a diagnosis of CLE irrespective of the presence of SLE, blood and plasma drug concentration-time data receiving multiple oral doses of HCQ sulfate (200-400 mg daily) were analyzed using nonlinear mixed-effects model software. The blood and plasma concentrations of HCQ were analyzed using a high-performance liquid chromatography tandem mass spectrometry method. Model evaluation and validation were performed using goodness-of-fit (GOF) plots, visual predictive check, and a bootstrap. RESULTS: The PopPKs of HCQ in the blood and plasma of 90 Japanese patients with CLE/SLE were well described by a 1-compartment model with first-order absorption and absorption lag time. Body weight was a significant (P < 0.001) covariate of oral clearance of HCQ. The final model was assessed using GOF plots, a bootstrap, and visual predictive check, and this model was appropriate. Simulations based on the final model suggested that the recommended daily doses of HCQ sulfate (200-400 mg) based on the ideal body weight in Japanese patients with CLE/SLE were in the similar concentration ranges. CONCLUSIONS: The PopPK models derived from both blood and plasma HCQ concentrations of Japanese patients with CLE/SLE were developed and validated. Based on this study, the dosage regimens of HCQ sulfate for Japanese patients with CLE/SLE should be calculated using the individual ideal body weight.
BACKGROUND:Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations. However, in Japan, HCQ has not been approved for CLE or SLE. To establish an appropriate therapeutic regimen and to clarify the pharmacokinetics (PK) of HCQ in Japanese patients with CLE with or without SLE (CLE/SLE), a population pharmacokinetic (PopPK) analysis was performed. METHODS: In a clinical study of Japanese patients with a diagnosis of CLE irrespective of the presence of SLE, blood and plasma drug concentration-time data receiving multiple oral doses of HCQ sulfate (200-400 mg daily) were analyzed using nonlinear mixed-effects model software. The blood and plasma concentrations of HCQ were analyzed using a high-performance liquid chromatography tandem mass spectrometry method. Model evaluation and validation were performed using goodness-of-fit (GOF) plots, visual predictive check, and a bootstrap. RESULTS: The PopPKs of HCQ in the blood and plasma of 90 Japanese patients with CLE/SLE were well described by a 1-compartment model with first-order absorption and absorption lag time. Body weight was a significant (P < 0.001) covariate of oral clearance of HCQ. The final model was assessed using GOF plots, a bootstrap, and visual predictive check, and this model was appropriate. Simulations based on the final model suggested that the recommended daily doses of HCQ sulfate (200-400 mg) based on the ideal body weight in Japanese patients with CLE/SLE were in the similar concentration ranges. CONCLUSIONS: The PopPK models derived from both blood and plasma HCQ concentrations of Japanese patients with CLE/SLE were developed and validated. Based on this study, the dosage regimens of HCQ sulfate for Japanese patients with CLE/SLE should be calculated using the individual ideal body weight.
Authors: Anil R Maharaj; Huali Wu; Christoph P Hornik; Stephen J Balevic; Chi D Hornik; P Brian Smith; Daniel Gonzalez; Kanecia O Zimmerman; Daniel K Benjamin; Michael Cohen-Wolkowiez Journal: JAMA Pediatr Date: 2020-10-05 Impact factor: 16.193
Authors: Naomi B Haas; Leonard J Appleman; Mark Stein; Maryann Redlinger; Melissa Wilks; Xiaowei Xu; Angelique Onorati; Anusha Kalavacharla; Taehyong Kim; Chao Jie Zhen; Sabah Kadri; Jeremy P Segal; Phyllis A Gimotty; Lisa E Davis; Ravi K Amaravadi Journal: Clin Cancer Res Date: 2019-01-11 Impact factor: 12.531
Authors: S Ruiz; D Concordet; T Lanot; B Georges; P Goudy; S Baklouti; C Mane; E Losha; H Vinour; D Rousset; M Lavit; V Minville; J-M Conil; P Gandia Journal: Int J Antimicrob Agents Date: 2020-11-28 Impact factor: 5.283
Authors: Stephen J Balevic; Thomas P Green; Megan E B Clowse; Amanda M Eudy; Laura E Schanberg; Michael Cohen-Wolkowiez Journal: Clin Pharmacokinet Date: 2019-04 Impact factor: 5.577
Authors: Stephen J Balevic; Christoph P Hornik; Thomas P Green; Megan E B Clowse; Daniel Gonzalez; Anil R Maharaj; Laura E Schanberg; Amanda M Eudy; Geeta K Swamy; Brenna L Hughes; Michael Cohen-Wolkowiez Journal: J Rheumatol Date: 2020-05-11 Impact factor: 5.346
Authors: Antonio Gonçalves; Julie Bertrand; Ruian Ke; Emmanuelle Comets; Xavier de Lamballerie; Denis Malvy; Andrés Pizzorno; Olivier Terrier; Manuel Rosa Calatrava; France Mentré; Patrick Smith; Alan S Perelson; Jérémie Guedj Journal: CPT Pharmacometrics Syst Pharmacol Date: 2020-08-07
Authors: Azrin N Abd-Rahman; Louise Marquart; Nathalie Gobeau; Anne Kümmel; Julie A Simpson; Stephan Chalon; Jörg J Möhrle; James S McCarthy Journal: Clin Pharmacol Ther Date: 2020-07-02 Impact factor: 6.903